RU44790 belongs to a new class of synthetic
monocyclic beta-lactam antibiotics which feature a bioisosteric
tetrazole moiety instead of the more classical acidic functions at the N-1 position of the
beta-lactam ring. Its antibacterial activity was evaluated against some 900 strains and was compared with those of other recent
beta-lactam derivatives, especially
aztreonam.
RU44790 is endowed with potent activity against gram-negative bacteria. At less than or equal to 0.6 micrograms/ml,
RU44790 inhibited 90% of all strains of the family Enterobacteriaceae with the exception of Citrobacter spp. (MIC for 90% of strains tested, 1.2 micrograms/ml). The activity was similar to that of
aztreonam against strains that are normally susceptible to expanded-spectrum
cephalosporins. On the other hand, the new compound was 10 to 100 times more potent than
aztreonam and most of the other
antibiotics tested against enterobacteria that produce chromosome-encoded or plasmid-mediated extended-spectrum
beta-lactamases. Pseudomonas aeruginosa isolates were equally susceptible to both
monobactams.
RU44790 was inactive against staphylococci and had only marginal activity against streptococci (MIC for 50% of strains tested, 2.5 micrograms/ml).
RU44790 was highly resistant to hydrolysis by various
beta-lactamases, particularly cephalosporinases such as P99. The latter
enzyme was also inhibited by the compound.
RU44790 showed a high affinity for
penicillin-binding protein 3 of Escherichia coli. The results suggest that
RU44790 has good potential in the treatment of
infections caused by gram-negative microorganisms.